Bens Clinic Nagoya to Introduce Next-Gen ECM Skin Boosters 'TISSIVO' and 'Re2O (BNAJU)' in September 2026

Bens Clinic Nagoya (located in Nagoya City, Aichi Prefecture), a cosmetic dermatology clinic, plans to introduce the next-generation skin boosters 'TISSIVO' and 'Re2O (BNAJU)' starting September 2026. These treatments focus on the skin's structure and condition, offering a new dimension in aesthetic care.

In recent years, South Korea's aesthetic medicine field has seen growing interest in skin boosters that target the extracellular matrix (ECM)—the foundational structure of the skin—rather than simply replenishing cosmetic ingredients.

The 'TISSIVO' and 'Re2O (BNAJU)' products that Bens Clinic Nagoya plans to introduce are both based on human acellular dermal matrix (hADM: human Acellular Dermal Matrix).

By focusing on the ECM concept, which differs from traditional skin boosters, the clinic aims to offer a new aesthetic treatment option for concerns related to skin firmness, elasticity, and texture.

At Bens Clinic Nagoya, each patient will undergo a physician consultation and examination to assess their individual skin condition and concerns before determining the suitability of the treatment.

Next-Generation ECM Skin Booster 'TISSIVO'

'TISSIVO' is an ECM platform product based on human acellular dermal matrix (hADM).

ECM (extracellular matrix) refers to a collective term for components that exist around cells and support the structure and environment of tissues.

According to official TISSIVO information, it is introduced as a product based on human acellular dermal matrix, focusing on components that constitute dermal ECM, such as collagen, elastin, and hyaluronic acid. The product line features finely engineered particle designs.

Bens Clinic Nagoya plans to introduce TISSIVO as a new skin care option that emphasizes the ECM concept.

However, the appropriate treatment method varies depending on skin condition, treatment area, and injection technique. Therefore, the physician will determine the specific approach after examination.

'Re2O (BNAJU)'—Known in Korea

'Re2O' is a skin booster developed by South Korea's Humedix under the Elravie brand, with hADM as its main ingredient. In Japan, it is sometimes introduced under the name 'BNAJU'. Some Japanese aesthetic clinics present Re2O, Rituwo, and BNAJU as the same product. Re2O is characterized by its approach of micronizing human acellular dermal matrix (hADM) and injecting it into the dermal layer of the skin.

General skin boosters often use various ingredients such as hyaluronic acid and polynucleotides to improve skin condition.

In contrast, Re2O focuses on the ECM that constitutes skin structure, aiming to directly replenish the extracellular matrix of human-derived dermis containing collagen and elastin.

Bens Clinic Nagoya plans to introduce Re2O as an option for patients interested in Korean aesthetic medicine, offering a new approach to skin care.

What is hADM—Common to Both 'TISSIVO' and 'Re2O'

hADM stands for human Acellular Dermal Matrix.

It refers to a material derived from human skin tissue, where cellular components have been removed, leaving the extracellular matrix (ECM) of the dermis for use.

ECM contains components related to skin tissue structure and environment, including collagen, elastin, hyaluronic acid, and glycosaminoglycans.

TISSIVO is officially introduced as an ECM platform based on hADM, and Re2O is also presented by medical institutions in Japan as an hADM-based skin booster.

However, the use of hADM itself does not guarantee the treatment's efficacy or safety.

In actual practice, physicians will assess suitability based on the patient's skin condition, medical history, allergy history, and current medications.

This treatment is suitable for individuals who:

- Are concerned about loss of skin firmness and elasticity - Are concerned about skin texture and smoothness - Notice skin changes due to dryness - Are concerned about enlarged pores - Feel changes in skin quality with aging - Are interested in skin care trending in Korea - Are considering alternatives to conventional skin boosters - Want to consult on personalized aesthetic treatments based on skin condition - Wish to receive Korean-style aesthetic treatments in Nagoya

Physician Consultation at Bens Clinic Nagoya

Skin quality and concerns vary from person to person.

Therefore, our clinic does not uniformly recommend either 'TISSIVO' or 'Re2O'. Instead, physicians will determine treatment suitability after confirming each patient's skin condition and preferences.

Additionally, hADM-based treatments may not be suitable for some patients depending on their condition.

Before treatment, we will explain the procedure, products used, treatment method, costs, expected outcomes, risks, and side effects, ensuring patients fully understand before proceeding.

Risks and Side Effects Associated with Treatment

Since both TISSIVO and Re2O involve injection procedures, patients may experience redness, swelling, pain, bruising, or tenderness at the injection site.

Immediately after injection, swelling or unevenness at the injection site may occur.

Depending on skin condition and injection method, swelling and redness may last for several days.

Rarely, infection, inflammation, nodules, or allergic reactions may occur.

For products using human-derived tissue, product-specific risks must also be evaluated.

Additionally, post-treatment recovery and individual responses vary.

For detailed information on risks and side effects, please consult with the physician during the pre-treatment consultation.

Important Notice Regarding Unapproved Pharmaceuticals and Medical Devices

The regulatory approval status of 'TISSIVO' and 'Re2O (BNAJU)' under Japan's Pharmaceutical and Medical Device Act differs from that of domestically approved products.

In particular, Re2O (BNAJU) is confirmed to be introduced by some medical institutions in Japan as an unapproved pharmaceutical.

Even if a product is approved or authorized overseas, such approval does not equate to approval under Japan's Pharmaceutical and Medical Device Act.

Re2O is introduced as a product approved by Korea's MFDS.

On the other hand, for TISSIVO, publicly available information confirms it is an hADM-based ECM product available in Korea, but its approval status in Japan and specific regulatory classification in Korea require final verification based on official regulatory documentation.

Therefore, our clinic will confirm the actual product information and regulatory classification before providing necessary information to patients.

[Regarding Re2O (BNAJU)]

Approval status in Japan: In Japan